Support Local Journalism. Join the Cleveland Scene Press Club.

Sunday, August 2, 2020

Dr. Fauci Says Hydroxychloroquine Study Touted by Trump is 'Flawed'

Posted By on Sun, Aug 2, 2020 at 9:37 AM

  • White House/Andrea Hanks
Dr. Anthony Fauci is among the experts who are critical of a study by Detroit's Henry Ford Health System that found the drug hydroxychloroquine lowered the death rate in COVID-19 patients.

The study made waves when its results were announced earlier this month because they contradicted a number of other high-profile studies that found the drug was not effective in treating the coronavirus. (Some earlier studies were even abruptly halted after patients were found to be more likely to suffer cardiac side effects on the drug.) President Donald Trump was quick to say the study vindicated him, as he has long touted the potential of the drug to be a "game-changer" in fighting COVID-19.

But when asked about the study during a congressional testimony on Friday, Fauci said it was "flawed" and had "a number of issues."

The study analyzed 2,541 COVID-19 patients and found 13% of those treated with hydroxychloroquine died, while 26% of those who did not receive the drug died.

But the issue, Fauci said, is that the study was not a randomized, double-blind study — which is considered "the gold standard" in science. In other words, doctors carefully selected who received the treatment, which could skew the results.

Fauci said that some of the patients were also receiving corticosteroids, which could have influenced the results further.

"That study is a flawed study, and I think anyone who examines it carefully is that it is not a randomized placebo-controlled trial," Fauci said.

When Rep. Blaine Luetkemeyer, a Republican from Missouri, interrupted Fauci, saying the study had been peer-reviewed, Fauci reiterated the importance of randomized, double-blind studies.

"It doesn't matter, you can peer-review something that's a bad study," Fauci said. "The fact is it is not a randomized placebo-controlled trial. The point that I think is important, because we all want to keep an open mind, any and all of the randomized placebo-controlled trials, which is the gold standard of determining if something is effective, none of them have shown any efficacy for hydroxychloroquine."

While Henry Ford is conducting a randomized, double-blind study of hydroxychloroquine as a prophylaxis, or measure to prevent COVID-19, it has not yet released the results of that study. It was expected to wrap up this month.

Hydroxychloroquine could very well prove to be an effective treatment for some COVID-19 patients, but a randomized, double-blind study has not yet found that to be the case.

And if one does, "I would be the first one to admit it and promote it," Fauci said.

Trump has accused the mainstream media and scientists of suppressing information about hydroxychloroquine out of political spite.

"The highly respected Henry Ford Health System just reported, based on a large sampling, that HYDROXYCHLOROQUINE cut the death rate in certain sick patients very significantly," he tweeted earlier this month. "The Dems disparaged it for political reasons (me!). Disgraceful."

The drug was in the news again this week when a viral video showed a Houston doctor named Stella Emmanuel saying that, "This virus has a cure: It’s called hydroxychloroquine." The video was removed or flagged as false information by social media platforms Facebook, Twitter, and Instagram.

Immanuel also believes in alien DNA, lizard people, and something called "demon semen," so it's probably safe to say she's a bit of a quack.

Tags: , ,

We welcome readers to submit letters regarding articles and content in Cleveland Scene. Letters should be a minimum of 150 words, refer to content that has appeared on Cleveland Scene, and must include the writer's full name, address, and phone number for verification purposes. No attachments will be considered. Writers of letters selected for publication will be notified via email. Letters may be edited and shortened for space.

Email us at

Support Local Journalism.
Join the Cleveland Scene Press Club

Local journalism is information. Information is power. And we believe everyone deserves access to accurate independent coverage of their community and state. Our readers helped us continue this coverage in 2020, and we are so grateful for the support.

Help us keep this coverage going in 2021. Whether it's a one-time acknowledgement of this article or an ongoing membership pledge, your support goes to local-based reporting from our small but mighty team.

Join the Cleveland Scene Press Club for as little as $5 a month.

Read the Digital Print Issue

January 5, 2022

View more issues


Never miss a beat

Sign Up Now

Subscribe now to get the latest news delivered right to your inbox.


© 2022 Cleveland Scene: 737 Bolivar Rd., Suite 4100, Cleveland, OH 44115, (216) 505-8199
Logos and trademarks on this site are property of their respective owners.

Website powered by Foundation